FY2025 EPS Estimates for Kura Oncology Boosted by Analyst

Kura Oncology, Inc. (NASDAQ:KURA) – Brookline Capital Management raised their FY2025 earnings estimates for shares of Kura Oncology in a report issued on Thursday, November 21st. Brookline Capital Management analyst L. Cann now anticipates that the company will earn ($1.74) per share for the year, up from their prior forecast of ($2.27). The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. Brookline Capital Management also issued estimates for Kura Oncology’s FY2026 earnings at $0.95 EPS, FY2027 earnings at $3.16 EPS and FY2028 earnings at $5.97 EPS.

A number of other analysts have also commented on the company. Jefferies Financial Group lowered their price objective on Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a report on Thursday. Bank of America decreased their target price on Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research report on Friday. TD Cowen reiterated a “buy” rating on shares of Kura Oncology in a report on Thursday. Finally, Lifesci Capital upgraded shares of Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Kura Oncology currently has an average rating of “Moderate Buy” and an average target price of $29.38.

Kura Oncology Price Performance

KURA opened at $10.80 on Monday. The company’s 50 day simple moving average is $17.88 and its 200-day simple moving average is $19.67. Kura Oncology has a one year low of $9.06 and a one year high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The stock has a market capitalization of $839.81 million, a P/E ratio of -4.58 and a beta of 0.86.

Institutional Trading of Kura Oncology

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its position in Kura Oncology by 2.4% during the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock worth $34,798,000 after buying an additional 41,535 shares during the last quarter. Barclays PLC lifted its holdings in Kura Oncology by 104.5% during the 3rd quarter. Barclays PLC now owns 165,484 shares of the company’s stock valued at $3,234,000 after purchasing an additional 84,563 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of Kura Oncology by 36.7% in the third quarter. Jane Street Group LLC now owns 126,085 shares of the company’s stock valued at $2,464,000 after purchasing an additional 33,848 shares during the last quarter. Point72 DIFC Ltd bought a new position in shares of Kura Oncology in the third quarter valued at about $146,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Kura Oncology during the 3rd quarter worth about $3,695,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.